US FDA Grants Nod For Clinical Trials of Lamassu Biotech's Cancer Treatment

Lamassu Bio Inc., a cutting-edge biotech organization, is pleased to report that its spearheading work to battle privately progressed metastatic p53 wild-type cancers has secured investigational new drug application (IND) endorsement from the US FDA to continue in start stage 1/2a clinical preliminaries.

The preliminary will explore a novel SA53-operating system, a hereditarily designated treatment for the MDM2 protein, a critical controller of the tumor suppressor p53 gene. By specifically enacting p53, Lamassu expects to prompt tumor cell passing and repress development, possibly giving a genuinely necessary forward leap in designated disease treatment.

The firm has been working in a joint effort with the Cleveland Clinic on this preliminary, driven by Peter Anderson, MD, which looks to foster another cancer treatment for patients with restricted helpful choices. With useful p53 present in about portion, the possible effect of this therapy could be extraordinary in the battle against cancer.

The IND endorsement by the US FDA follows Lamassu's receiving one of the National Institutes of Health's biggest accessible SBIR award grants to assist with sending off the clinical trial review for its creative approach to malignant cancer treatment.

"This approval is the result of the vision and tenacity of our entire Lamassu team and our partners," said Dr. Gabi Hanna, CEO of Lamassu. "It is a critical step to move beyond conventional chemotherapy to targeted therapy to bring hope and healing to millions who suffer from stubborn cancers that don't respond to conventional treatments and to reduce the toxicity of cancer treatments. With SA53-OS patented in 69 countries, successful trials could make a significant impact on the global fight against cancer."

"The initiation of this trial adds to Lamassu's record of accelerating drug development, delivering innovative therapies that can go from the laboratory to the bedside faster and with improved outcomes," said Dr. Hanna.